These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38450559)
1. Theranostic Agent Targeting Bone Metastasis: A Novel [ Jin W; Zhao R; Wang R; Choi SR; Ploessl K; Alexoff D; Wu Z; Zhu L; Kung HF J Med Chem; 2024 Mar; 67(6):4793-4803. PubMed ID: 38450559 [TBL] [Abstract][Full Text] [Related]
2. A New [ Zha Z; Wu Z; Choi SR; Ploessl K; Smith M; Alexoff D; Zhu L; Kung HF Mol Pharm; 2020 May; 17(5):1674-1684. PubMed ID: 32251600 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of 68 Ga- or 177 Lu-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases : A Phase 0/I Study. Qiu L; Wang Y; Liu H; Wang Q; Chen L; Liu L; Wang L; Feng Y; Chen Y Clin Nucl Med; 2023 Jun; 48(6):489-496. PubMed ID: 36976706 [TBL] [Abstract][Full Text] [Related]
4. Comparative preclinical evaluation of Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651 [TBL] [Abstract][Full Text] [Related]
5. Preliminary results of biodistribution and dosimetric analysis of [ Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560 [TBL] [Abstract][Full Text] [Related]
6. New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177). Zha Z; Choi SR; Li L; Zhao R; Ploessl K; Yao X; Alexoff D; Zhu L; Kung HF J Med Chem; 2022 Oct; 65(19):13001-13012. PubMed ID: 36103652 [TBL] [Abstract][Full Text] [Related]
7. Huang J; Zhang X; Liu Q; Gong F; Huang Y; Huang S; Fu L; Tang G J Med Chem; 2024 Oct; 67(19):17785-17795. PubMed ID: 39321030 [TBL] [Abstract][Full Text] [Related]
8. Value of post-therapy Tuncel M; Telli T Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):114-117. PubMed ID: 28750750 [TBL] [Abstract][Full Text] [Related]
9. [ Shi S; Zhang L; Wu Z; Zhang A; Hong H; Choi SR; Zhu L; Kung HF Nucl Med Biol; 2020; 82-83():17-24. PubMed ID: 31869735 [TBL] [Abstract][Full Text] [Related]
11. A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting. Meckel M; Kubíček V; Hermann P; Miederer M; Rösch F Nucl Med Biol; 2016 Nov; 43(11):670-678. PubMed ID: 27560354 [TBL] [Abstract][Full Text] [Related]
12. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent. Ogawa K; Takai K; Kanbara H; Kiwada T; Kitamura Y; Shiba K; Odani A Nucl Med Biol; 2011 Jul; 38(5):631-6. PubMed ID: 21718937 [TBL] [Abstract][Full Text] [Related]
17. Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies. Eder M; Wängler B; Knackmuss S; LeGall F; Little M; Haberkorn U; Mier W; Eisenhut M Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1878-86. PubMed ID: 18509635 [TBL] [Abstract][Full Text] [Related]
18. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid. Meckel M; Bergmann R; Miederer M; Roesch F EJNMMI Radiopharm Chem; 2017; 1(1):14. PubMed ID: 29564390 [TBL] [Abstract][Full Text] [Related]
19. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548 [TBL] [Abstract][Full Text] [Related]
20. [ Hong H; Zha Z; Zhao R; Luo Y; Jin W; Li L; Wang R; Yan L; Wang H; Ploessl K; Qiao J; Zhu L; Kung HF Mol Pharm; 2023 Apr; 20(4):2159-2169. PubMed ID: 36942924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]